Ruxolitinib Rutinib Cream 1.5% is an advanced topical pharmaceutical formulation designed specifically for the treatment of inflammatory and pigmentary skin disorders such as atopic dermatitis (eczema) and vitiligo. This cream harnesses the potent immunomodulatory effects of Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor, to effectively reduce immune-mediated inflammation and promote the repigmentation process in depigmented skin patches. Suitable for precise topical application, the cream is intended to be applied directly on affected skin areas as per medical prescription, providing targeted relief and skin restoration without systemic exposure. Manufactured under stringent quality and safety protocols, Ruxolitinib Rutinib Cream 1.5% ensures consistent potency, stability, and patient safety, making it a reliable option for dermatologists and healthcare providers managing chronic skin conditions. Its innovative mechanism offers a promising alternative to conventional corticosteroid therapies, minimizing side effects such as skin thinning while delivering effective clinical outcomes.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ruxolitinib 1.5% |
| Mechanism of Action | Selective Janus kinase (JAK) 1 and 2 inhibition to reduce inflammation and aid skin repigmentation |
| Indications | Treatment of atopic dermatitis (eczema) and vitiligo |
| Formulation | Topical cream for direct application to affected skin areas |
| Prescription Status | Available only with medical prescription |
| Quality Standards | Manufactured under stringent quality control and safety protocols |
| Application Guidelines | Apply as directed by healthcare professional for optimal efficacy and safety |
| Safety Profile | Minimized systemic exposure, reduced risk of skin thinning compared to corticosteroids |
| Packaging | Comes in secure, sealed tubes ensuring product integrity |
| Target Market | Dermatology clinics, hospitals, healthcare providers specializing in skin disorders |
| Attributes | Description |
|---|---|
| Concentration | 1.5% Ruxolitinib |
| Dosage Form | Topical cream |
| Color and Texture | White to off-white smooth cream |
| Storage Conditions | Store below 25°C, protect from light and moisture |
| Shelf Life | Typically 24 months from manufacturing date |
| Manufacturer Compliance | Produced in GMP-certified facility |
| Usage Instructions | Apply a thin layer on affected area twice daily or as prescribed |
| Package Size | Available in 15g and 30g tubes |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Ruxolitinib Rutinib Cream 1.5% works by selectively inhibiting JAK enzymes to modulate immune response without the side effects typically associated with corticosteroids such as skin thinning or hormonal imbalances.
Yes, the cream is formulated for ongoing management under medical supervision, offering a safer profile for long-term use in conditions like vitiligo and eczema.
Patients should avoid applying the cream on infected or open wounds, follow prescribed dosages, and use protective measures to avoid sun exposure on treated areas to enhance effectiveness and safety.
Combination use should only be done under healthcare provider guidance to avoid potential drug interactions or skin irritation.
The cream should be stored below 25°C in a dry place away from direct sunlight and moisture to preserve its stability and potency.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
